A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of BEY2153 After Oral Administration in Healthy Young and Elderly Male Volunteers.
Latest Information Update: 07 Nov 2022
Price :
$35 *
At a glance
- Drugs BEY 2153 (Primary)
- Indications Alzheimer's disease
- Focus First in man; Pharmacokinetics
- Sponsors BeyondBio
- 26 Nov 2020 Status changed from not yet recruiting to recruiting.
- 24 Jul 2020 New trial record